Merck Announces First Quarter Earnings Per Share Guidance and Raises Full-Year 2007 Earnings Per Share Guidance
This guidance does not reflect the establishment of any reserves for any potential liability relating to the Vioxx litigation.
Merck will hold a first-quarter 2007 sales and earnings conference call with institutional investors and analysts beginning at 9 a.m. ET on Thursday, April 19. During this call, Richard T. Clark, chief executive officer and president, and Judy C. Lewent, executive vice president and chief financial officer, will provide an overview of Merck's financial performance for the quarter. The first-quarter sales and earnings press release and supplemental financial disclosures will be issued that day, prior to the start of the conference call.
Institutional investors and analysts can participate in the call by dialing (706) 758-9927 or (877) 381-5782. Journalists are invited to listen only by calling (706) 758-9928 or (800) 399-7917. A replay of the call will be available starting at 11 a.m. ET on April 19 through 5 p.m. ET on April 26. To listen to the replay, dial (706) 645-9291 or (800) 642-1687 and enter ID # 1307506.
Investors, journalists and the general public may access a live audio webcast of the call on Merck's website at http://www.merck.com/newsroom/webcast. Software needed to listen to the webcast is available on the corporate website and should be downloaded prior to the beginning of the webcast. A replay of the webcast will be available from 11 a.m. ET on April 19 through 5 p.m. ET on April 26.
Merck & Co., Inc. is a global research-driven pharmaceutical company dedicated to putting patients first. Established in 1891, Merck discovers, develops, manufactures and markets vaccines and medicines to address unmet medical needs. The Company devotes extensive efforts to increase access to medicines through far-reaching programs that not only donate Merck medicines but help deliver them to the people who need them. Merck also publishes unbiased health information as a not-for-profit service. For more information, visit www.merck.com.
This press release contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and involve risks and uncertainties, which may cause results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential or financial performance. No forward-looking statement can be guaranteed, and actual results may differ materially from those projected. Merck undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise. Forward-looking statements in this press release should be evaluated together with the many uncertainties that affect Merck's business, particularly those mentioned in the cautionary statements in Item 1 of Merck's Form 10-K for the year ended Dec. 31, 2005, and in its periodic reports on Form 10-Q and Form 8-K, which the Company incorporates by reference.
Merck & Co., Inc.
Amy Rose, 908-423-6537
Graeme Bell, 908-423-5185
Posted: February 2007